A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC

Authors

Thomas Churilla

Publication/Presentation Date

2-2018

Volume

36

Issue

6

Disciplines

Medicine and Health Sciences | Oncology

Department(s)

Department of Radiation Oncology

Document Type

Article

Share

COinS